John Conley

Windgap Medical is developing health care products that meet the demands of your lifestyle. Our first product will improve the quality of life for patients living with severe allergies. X

MIT VMS supports innovation and entrepreneurial activity throughout the MIT community by matching prospective and experienced entrepreneurs with skilled, objective - volunteer mentors. We use a team mentoring approach with groups of 3 to 4 mentors sitting with the entrepreneur(s) in sessions that provide practical, day-to-day professional advice and coaching. VMS mentors are selected for their experience in areas relevant to the needs of new entrepreneurs and for their enthusiasm for the program. VMS assistance is given across a broad range of business activity, including product development, marketing, intellectual property law, finance, human resources, and founders issues. VMS services are offered without charge to MIT students, alumni, faculty and staff in the Boston area. VMS complements and cooperates with the many MIT centers and programs promoting innovations and entrepreneurship. MIT VMS Model • Unique Team Mentoring methodology • Strict code of ethics to assure objective, conflict-free and confidential advice • Best practices for screening, training and retaining a community of highly qualified and committed volunteer mentors • Focus on developing the entrepreneur as well as their venture • Practical, actionable advice • Formal operational processes

Windgap Medical is developing health care products that meet the demands of your lifestyle. Our first product will improve the quality of life for patients living with severe allergies. X

Launchpad Venture Group is a Boston-area angel investing group focused on locally based, early stage companies, primarily in high tech and life sciences. Launchpad is the most active Seed funder in the region having backed over 150 start ups. Launchpad specializes in leading priced equity raises. Launchpad invests approximately $10 million per year and actively syndicates with other Angel Groups and Venture Capitalists. You can learn more at www.launchpadventuregroup.com.

To those who say “impossible, impractical, unrealistic,” we say: “CHALLENGE ACCEPTED.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring RNAi-based medicines to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Alnylam is turning scientific possibility into reality - in 2018, the FDA and EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. We now have four additional medicines on the market. Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of 1,900+ people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer 3 years in a row ('19-'21), a Boston Globe Top Place to Work 8x in a row ('15-'21) and Fast Company's #1 Best Workplace for Innovators ('22 We are based in Cambridge, U.S., with offices throughout Europe, Asia, and South America. We invite you to connect with us by following us on LinkedIn, Facebook (@AlnylamPharma) Twitter (@Alnylam), Instagram (@AlnylamPharma) and YouTube. See our community guidelines: https://bit.ly/2FcRhJy.